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conclusions reported in this article are those 








failure.	 Among	 the	 cohort,	 15.6%	 filled	 benzodiazepine	 prescriptions	 in	 the	 year	
before	 transplant,	 and	 14.0%	 filled	 benzodiazepine	 prescriptions	 in	 the	 year	 after	
transplant	 (short-acting,	 9.5%;	 long-acting,	 3.3%;	 both	 1.1%).	 Use	 of	 short-acting	
benzodiazepines	in	the	year	before	transplant	was	associated	with	a	22%	increased	
risk of death in the year after transplant (aHR, 1.081.221.38),	while	use	of	all	classes	
in	the	year	after	transplant	was	associated	with	increased	risk	of	death	from	>1 to 
5 years (aHR: short-acting 1.291.391.48; long-acting 1.121.251.40;	 both	 1.461.742.07).	





stand mechanisms of risk relationships.
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1  | INTRODUC TION
In the general population, prescription opioid use for the treat-
ment	of	 acute	 and	 chronic	pain	 is	 associated	with	opioid-related	
complications, such as addiction, overdose, and death.1-3	 Use	 of	
benzodiazepines	in	combination	with	opioids	may	further	increase	




with	opioid	use	alone.4	Due	 to	 these	 risks,	 the	2016	Centers	 for	
Disease	Control	and	Prevention	Guideline	for	Prescribing	Opioids	
for	Chronic	Pain	recommended	that	physicians	avoid	co-prescrib-
ing	 benzodiazepines	 and	 opioids	 whenever	 possible.5	 This	 rec-
ommendation	 also	 applies	 when	managing	 pain	 in	 patients	 with	
chronic kidney disease.6
Previously,	 we	 have	 examined	 linkages	 of	 national	 transplant	
registries	 with	 pharmaceutical	 fill	 records	 to	 study	 opioid	 use	 in	
organ transplant recipients.7-9	 Administrative	 databases	 allow	 for	





in	 the	 first	 3	 years	 following	 transplant.7	 Pre-	 and	post-transplant	
opioid	use	was	associated	with	a	graded	increased	risk	of	death	and	
all-cause graft failure after kidney transplantation.8,10 Similar risk re-
lationships	were	recently	documented	among	liver	and	heart	trans-
plant recipients.9,11	Opioid	use	before	living	donor	nephrectomy	was	





ined adverse clinical events.13 In the kidney transplant population, 
concurrent	use	of	benzodiazepines	and	opioids	with	outcomes	has	
not	 been	 characterized.	 In	 this	 study,	 we	 examined	 linked	 regis-
try and pharmacy fill records for a large national sample of kidney 





We	conducted	a	 retrospective	cohort	 study	using	 linked	health-
care	databases	in	the	United	States	(US)	to	ascertain	patient	char-
acteristics, pharmacy fill records, and outcome events for kidney 
transplant	 recipients.	 This	 study	 used	 data	 from	 the	 Scientific	
Registry	 of	 Transplant	 Recipients	 (SRTR).	 The	 SRTR	 system	 in-
cludes	 data	 on	 all	 donors,	 waitlist	 candidates,	 and	 transplant	
recipients	 in	 the	 US,	 submitted	 by	 the	 members	 of	 the	 Organ	
Procurement	 and	 Transplantation	 Network	 (OPTN).	 The	 Health	
Resources	and	Services	Administration	(HRSA),	US	Department	of	
Health and Human Services, provides oversight to the activities of 
the	OPTN	and	SRTR	contractors.
Pharmacy	 claims	 data	 (PCD)	 were	 assembled	 by	 linking	 SRTR	





scription claims aggregated from multiple sources including claims 
warehouses,	 retail	 pharmacies,	 and	 prescription	 benefit	 managers	
for	approximately	60%	of	US	retail	pharmacy	transactions.	Individual	
claim	records	include	the	date	of	a	given	pharmacy	fill	with	the	na-
tional	 drug	 code	 identifying	 agent	 and	 dosage.	 After	 Institutional	
Review	Board	and	HRSA	approvals,	PCD	records	were	 linked	with	
SRTR	records	for	kidney	transplant	recipients.	We	applied	a	deter-




HITECH-certified	 encryption	 technology.	 The	 patient	 deidentifica-
tion	software	employs	multiple	encryption	algorithms	in	succession	
















by	 the	 OPTN	 Transplant	 Candidate	 Registration	 and	 Transplant	
Recipient	Registration	forms	(Table	1).
Pharmacy	 fills	 for	benzodiazepines	and	opioids	 in	 the	year	be-
fore	 and	 in	 the	 year	 after	 transplant	 were	 ascertained	 from	 the	
PCD	 records.	We	 categorized	benzodiazepine	use	 as	 either	 short-	
or	 long-acting.	 Short-acting	 benzodiazepines	 included	 alprazolam,	
estazolam,	 lorazepam,	midazolam,	 oxazepam,	 temazepam,	 and	 tri-
azolam;	 long-acting	 benzodiazepines	 included	 chlordiazepoxide,	
clobazam,	 clonazepam,	 clorazepate,	 diazepam,	 and	 flurazepam.	
Pharmacy	 fills	 for	 opioids	 in	 the	 year	 before	 and	 after	 transplant	
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TA B L E  1  Distributions	of	clinical	traits	of	kidney	transplant	recipients	(n	=	103	694)	by	class	of	benzodiazepine	use	in	the	year	prior	to	
transplant	(2008-2017)
Baseline characteristics No use (N = 87 533) Short-acting (N = 10 456) Long-acting (N = 4206) Both (N = 1499)
Age,	years ‡  ‡  ‡ 
<18 5.1 0.6 2.8 0.6
18 to 30 7.8 7.4 6.8 9.9
31 to 45 19.6 21.9 20.3 23.4
46	to	59 36.1 39.7 39.6 39.9
≥60 31.4 30.5 30.6 26.3
Female 38.1 48.0‡ 44.1‡ 47.5‡
Race ‡ ‡ ‡
White 49.2 62.2 63.3 69.1
African-American 28.2 20.2 20.1 15.1
Hispanic 15.0 13.8 11.9 12.9
Other 7.6 3.8 4.7 2.9
Highest level of education ‡ *
College or higher 48.6 52.1 51.1 49.8
Grade/high	school 45.4 43.5 42.9 45.0
Missing 6.0 4.4 6.0 5.1
Employment status ‡ ‡ ‡
Working 30.9 27.4 27.2 25.4
Not	working 57.6 65.4 63.7 67.7
Missing 11.4 7.2 9.0 7.0
Health insurance type ‡  ‡  *
Private 34.4 32.3 31.3 31.4
Public 65.5 67.6 68.7 68.6
Missing 0.1 0.1 0.0 0.1
Body	mass	index,	kg/m2 ‡ *
<18.5 4.1 2.6 3.4 2.7
18.5-24.9 28.9 30.6 29.5 31.0
25.0-30.0 32.1 31.1 31.1 31.4
>30.0 33.7 34.4 34.7 33.9
Missing 1.3 1.4 1.3 1.0
Physical	capacity	status † † ‡
Not limited 48.6 48.6 48.4 52.4
Limited 5.0 5.9 6.3 6.5
Missing 46.4 45.5 45.3 41.1
Comorbid	conditions
Hypertension 73.2 73.6 72.2 73.1
Diabetes	mellitus 32.5 32.1 30.5* 29.0*
Coronary artery disease 4.8 5.3* 6.1‡  6.4*
Cerebral	vascular	disease 2.1 2.4 2.7* 2.2
Peripheral	vascular	disease 6.8 7.2 7.9* 7.3
COPD 1.2 1.7 ‡ 1.6* 1.3
Cause of ESRD ‡ ‡ ‡
Hypertension 25.1 23.4 22.0 20.5
Diabetes	mellitus 24.5 23.6 23.2 21.0
(Continues)
4 of 9  |     LAM et AL.
were	 normalized	 to	morphine	 equivalents	 (ME),	 according	 to	 con-
version	ratios	(SDC,	Table	S1).	Pre-	and	post-transplant	ME	were	ag-
gregated	for	each	recipient	and	expressed	as	dose	(mg)	of	annual	ME	
exposure.	We	 ranked	 annual	ME	 exposure	 among	 recipients	who	
filled	opioid	prescriptions	by	levels	as	follows:	level	I,	1-300	mg;	level	
II,	301-600	mg;	level	III,	601-1000	mg;	and	level	IV,	>1000 mg per 
year, similar to previous methods.7,9,10,12
2.3 | Outcome measurements
The	outcomes	of	interest	were	death	and	graft	failure	in	the	year	after	
transplant for the pretransplant use analyses and in the >1 to 5 years 
after	transplant	for	the	posttransplant	use	analyses.	Patient	death	was	
defined	as	death	from	any	cause.	In	secondary	analyses,	we	examined	
cause-specific death related to infections, malignancy, cardiovascular/
Baseline characteristics No use (N = 87 533) Short-acting (N = 10 456) Long-acting (N = 4206) Both (N = 1499)
Glomerulonephritis 23.1 25.1 24.1 27.9
Polycystic	kidney	disease 9.5 10.2 10.8 10.5
Other 17.8 17.8 19.9 20.1
Duration of dialysis, months ‡ ‡ ‡
None	(pre-emptive) 18.1 12.7 13.6 9.1
0.1-24 28.3 31.2 29.1 33.8
25-60 29.8 32.0 33.2 33.7
>60 23.4 23.7 23.7 23.1
Missing 0.3 0.3 0.4 0.3
Peak	PRA	level,	% ‡ ‡ ‡
<10 71.5 66.5 68.1 66.0
10 to 79 19.0 20.7 20.1 21.6
≥80 9.3 12.4 11.5 12.3
Missing 0.3 0.3 0.3 0.2
HLA	mismatches ‡ †
Zero	A,	B,	DR 6.8 7.9 7.4 9.5
Zero	DR 11.4 11.9 11.3 11.9
Other 81.8 80.2 81.3 78.7
Previous	organ	transplant 13.7 17.8‡ 17.7‡ 19.9‡
Era of current transplant * *
2008-2011 35.1 34.3 37.5 37.0
2012-2014 36.7 36.9 34.9 37.8
2015-2017 28.1 28.8 27.7 25.2
Donor type ‡
Living 34.4 37.2 35.0 36.7
Deceased	(SCD) 45.4 44.6 45.8 44.5
Deceased	(ECD) 9.1 7.9 8.5 8.3
Deceased	(DCD) 11.1 10.4 10.8 10.5
Cold ischemia time, hours *
≤12 49.6 51.1 48.7 51.2
13-24 33.5 32.9 34.8 34.1
25-36 9.8 9.3 9.4 9.2
>36 2.4 2.0 2.0 1.9




*P < .05-.002. 
†P = .001-.0002. 
‡P < .0001. 
TA B L E  1   (Continued)
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cerebrovascular,	 and	 other	 and	 unknown	 causes,	 as	 previously	 de-









els	 for	 the	 likelihood	of	 benzodiazepine	 use	 in	 the	 pretransplant	
period	were	constructed	by	multivariable	 logistic	 regression,	and	
regression	models	were	 adjusted	 by	 stratification	 for	 quintile	 of	
propensity score, as per previous methods.7-11,15	 Adjusted	 asso-
ciations	of	pretransplant	benzodiazepine	use	with	post-transplant	
death	and	all-cause	graft	 failure	 (adjusted	hazard	 ratio	with	95%	
upper	and	lower	confidence	limits,	LCLaHRUCL)	were	quantified	by	
multivariate	 Cox	 regression	 including	 adjustment	 for	 recipient,	
donor,	 and	 transplant	 clinical	 factors.	 To	 assess	 impact	 of	 these	




all	outcome	analyses,	we	interpreted	two-tailed	P < .05 as statisti-
cally	 significant.	The	 study	 followed	guidelines	 for	observational	
studies	(SDC,	Table	S2).
3  | RESULTS









transplant;	 10.1%	 were	 prescribed	 a	 short-acting	 benzodiazepine,	
4.1%	 a	 long-acting	 benzodiazepine,	 and	 1.4%	 both.	 Patients	 who	
filled	benzodiazepines	were	more	likely	to	be	aged	46-59	years,	fe-
male,	white,	or	unemployed,	or	to	have	a	history	of	previous	organ	
transplant,	 than	 recipients	 without	 a	 benzodiazepine	 prescription	
fill	 in	the	year	prior	to	transplant.	Patterns	were	similar	for	kidney	
transplant	 recipients	 with	 benzodiazepine	 prescription	 fills	 in	 the	
year	 after	 transplant,	 during	which	14.0%	of	 recipients	 filled	ben-
zodiazepines	 (short-acting	 9.5%,	 long-acting	 3.3%,	 and	 both	 1.1%;	
SDC,	Table	S4).








death or graft failure over the first year post-transplant.
Risk	 relationships	 were	 more	 pronounced	 for	 benzodiazepine	
use	 in	the	first	year	post-transplant	with	death	and	graft	failure	 in	
the	 subsequent	>1	 to	5	years	 (SDC,	Table	S6).	 For	 example,	 com-
pared	with	no	use,	use	of	all	classes	of	benzodiazepines	was	asso-
ciated	with	 increased	risk	of	mortality	over	the	next	4	years	 (aHR:	
short-acting 1.291.391.48; long-acting 1.121.251.40;	 both	 1.461.742.07).	
Use	of	both	long-	and	short-acting	benzodiazepines	in	the	year	after	
transplant	was	also	associated	with	a	39%	increased	risk	of	all-cause	
graft failure (aHR, 1.211.391.60)	and	a	14%	increased	risk	of	death-cen-
sored graft failure (aHR, 0.931.141.39)	in	the	subsequent	>1 to 5 years, 
although the latter association did not reach statistical significance.
3.3 | Patterns of pre- and post-transplant 
benzodiazepine and opioid use
In	 the	 study	 cohort,	 40.2%	 of	 recipients	 filled	 a	 prescription	 for	











3.4 | Death and graft failure according to 
benzodiazepine and opioid use
After	adjustment	for	demographic	and	clinical	factors,	high-level	opi-
oid	use	in	the	year	prior	to	transplant	was	associated	with	increased	
risk	of	death	 in	 the	 first	year	post-transplant	 (SDC,	Table	S5).	While	
significant	 interactions	of	benzodiazepines	and	opioids	were	not	de-
tected,	there	appeared	to	be	additive	mortality	risks	in	patients	who	
filled	 both	 benzodiazepine	 and	 opioids.	 Compared	 with	 opioid	 and	











In addition to these associations, the risk of death and graft failure 
















capacity	quantified	by	c-statistics	was	similar	 to	 that	of	 the	group	
of	 comorbidities	 captured	 in	 the	 SRTR	 registry	 and	 greater	 than	
that	of	BMI	(Table	S7).	Pretransplant	benzodiazepine	and	opioid	use	
contributed	1.5%	to	overall	prediction	of	first	year	post-transplant	
death,	 compared	 to	 2.6%	 impact	 of	 combined	 comorbidities	 and	
0.3%	impact	of	BMI.	Post-transplant	benzodiazepine	and	opioid	use	
contributed	3.9%	to	overall	prediction	of	>1 to 5 years post-trans-
plant	 death,	 compared	 to	 2.1%	 impact	 of	 combined	 comorbidities	
and	0.3%	impact	of	BMI.
We	 examined	 cause	 of	 death	 reported	 to	 the	 registry.	 In	 the	
first	year	after	transplant,	distribution	of	reported	causes	of	death	
included:	 infection,	 20.4%;	 cardiovascular,	 24.4%;	 malignancy,	
4.9%;	other,	31.5%;	and	unknown,	18.8%.	Compared	 to	 recipients	
with	no	evidence	of	benzodiazepine	or	opioid	use	in	the	year	prior	
to	 transplant,	 recipients	 with	 both	 classes	 of	 benzodiazepine	 and	
the highest level of opioid use had a 2-fold increased risk of death 
due to infection (aHR, 1.182.204.12),	other	(aHR,	1.142.852.99),	and	un-
known	causes	 (aHR,	1.522.082.83),	but	no	statistically	significant	 in-
crease risk of death due to cardiovascular causes (aHR, 0.741.482.98)	
or malignancy (aHR, 0.401.072.85)	 (SDC,	 Table	 S8).	 Similar	 results	
were	 found	 in	 the	 post-transplant	 use	 analyses	 (aHR,	 infection:	
F I G U R E  1  Pre-	(A)	and	post-transplant	
(B)	opioid	use	according	to	class	of	
benzodiazepine	use
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F I G U R E  2  Adjusted	associations	of	post-transplant	benzodiazepine	and	opioid	use	and	death	and	graft	failure	in	the	subsequent	>1 to 5 y
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1.803.637.32; cardiovascular: 0.511.373.67; malignancy: 0.631.684.49; 
other: 0.951.833.53;	unknown:	2.012.773.81)	(SDC,	Table	S9).
4  | DISCUSSION
We	 examined	 novel	 linkages	 of	 national	 transplant	 registry	 data	
with	 a	 pharmaceutical	 claims	 warehouse	 to	 retrospectively	 study	
benzodiazepine	and	opioid	prescription	fills	among	a	large	national	
cohort	 of	 US	 kidney	 transplant	 recipients.	We	 found	 that	 use	 of	









who	 did	 not	 use	 either	medication,	 suggesting	 additive	 effects	 of	
these agents on post-transplant mortality risk.
Despite	the	burden	of	mood	disorders	and	chronic	pain	in	pa-
tients	with	end-stage	kidney	disease,	use	of	benzodiazepines	and	
opioids	 is	 understudied	 in	 this	 population.	 A	 systematic	 review	
of	15	studies	found	prevalence	of	benzodiazepine	use	 in	dialysis	
patients	 ranging	 from	 8%	 to	 26%,	 and	 prevalence	 of	 opioid	 use	
ranging	from	5%	to	36%.13	The	review	highlights	the	problems	of	
anxiety,	 depression,	 and	 pain	 in	 the	 dialysis	 population,	 and	 the	
variability	of	medication	use	and	methods	of	drug	reporting	across	
centers. Kidney transplant recipients are typically a healthier 
segment	of	the	population	with	kidney	failure	given	the	rigorous	
screening and selection process required in the assessment of 
transplant	candidates.	Our	study	found	that	16%	of	kidney	trans-
plant	 recipients	 filled	 a	 prescription	 for	 a	 benzodiazepine	 in	 the	
year	prior	to	transplant,	and	40%	filled	a	prescription	for	an	opi-










uncommon	 in	our	cohort	while	nearly	half	of	 recipients	 filled	an	
opioid prescription in the year prior to surgery.







azepine	and	opioid	use	 in	 kidney	 transplant	 recipients	 and	associ-
ated	outcomes.	We	found	that	recipients	who	filled	a	prescription	
for	 a	 benzodiazepine	were	more	 likely	 to	 fill	 a	 prescription	 for	 an	
opioid	in	the	pre-	and	post-transplant	periods.	Recipients	who	were	
prescribed	both	 short-	 and	 long-acting	benzodiazepines	were	 also	
more	likely	to	be	co-prescribed	higher	levels	of	opioids.	Use	of	both	





In	 the	 general	 population,	 concurrent	 use	 of	 benzodiazepines	
and opioids leads to increased opioid-related overdoses due to the 
additive respiratory depressant effects.4,20 In one study, prescrip-
tion	fills	for	both	benzodiazepines	and	opioids	were	associated	with	
a	2-fold	higher	risk	of	emergency	room	visits	or	hospitalizations	for	
opioid-related	overdoses,	 compared	with	prescription	 fills	 for	 opi-
oids alone.20	 Almost	 30%	of	 fatal	 opioid-related	 overdoses	 in	 the	
US	 are	 thought	 to	 also	 involve	 benzodiazepines.20	We	 found	 that	
recipients	who	filled	both	classes	of	benzodiazepines	along	with	the	





opioid use and the effects on post-transplant outcomes, such as 
death	and	graft	 loss.	We	used	novel	 linkages	of	a	 transplant	 reg-
istry	 to	 electronic	 prescription	 fills	 as	 a	 nonobtrusive	method	 to	
identify	opioid	use	that	circumvents	biases	 related	to	self-report.	
This	study	also	has	limitations.	While	prescription	fill	records	may	
be	 more	 accurate	 than	 patient	 self-reporting,	 we	 may	 have	 un-
derestimated	 benzodiazepine	 and	 opioid	 use	 given	 that	we	were	
unable	 to	 account	 for	 illicit	 drug	use	or	prescription	 fills	 at	 phar-
macies	not	included	in	our	databases.	These	patients	would	likely	
still	 be	categorized	as	high-level	users	 if	 they	 filled	most	of	 their	
benzodiazepine	and	opioid	prescriptions	at	the	same	pharmacy	as	











graft loss after kidney transplantation. Ongoing research is needed 
to	better	understand	the	mechanisms	of	these	risk	relationships	in	
this unique patient population.
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